The Outpatient Revolution: J&J Deal Signals Major Shift in Cardiac Care

NEW YORK, NY – August 10, 2026 – A multi-year strategic agreement announced today between Johnson & Johnson and ACCESS GPO, a physician-led purchasing organization, serves as the latest and most powerful signal yet of a tectonic shift in cardiovascular medicine. The deal, designed to bring Johnson & Johnson’s advanced cardiac electrophysiology (EP) technologies into ambulatory surgery centers (ASCs) nationwide, is more than a simple supply contract; it’s a key maneuver in the high-stakes migration of complex cardiac care from the traditional hospital to the efficient, cost-effective outpatient setting.

This partnership will equip ACCESS-affiliated centers with a sophisticated portfolio of technologies for treating cardiac arrhythmias, including three-dimensional mapping systems, intracardiac imaging, and both radiofrequency and the highly anticipated pulsed field ablation (PFA) systems. As demand for these procedures is projected to grow by over 5% annually—far outpacing the expansion of hospital lab capacity—this agreement is a strategic play to capture a market being fundamentally reshaped by economic pressures and technological advancement.

The New Frontier for Heart Rhythm Treatment

For decades, complex cardiac ablations—procedures that correct irregular heartbeats like atrial fibrillation—were the exclusive domain of large hospitals. The perceived risks and technological demands kept these life-altering treatments firmly within inpatient walls. That paradigm is now collapsing. The movement of EP procedures into ASCs represents, as Dr. Vijay Swarup, Executive Director of Arizona Heart Rhythm Center, noted, “one of the most important developments in cardiovascular care today.”

The shift is driven by a convergence of factors. Technologically, modern EP tools have become safer and more efficient, reducing procedure times and complication risks. Clinically, a growing body of evidence demonstrates that for appropriately selected patients, outcomes in an ASC are comparable to those in a hospital. This agreement with Johnson & Johnson, a global leader in the space through its Biosense Webster division, directly addresses the technology piece of the puzzle. It gives physician-led outpatient centers access to the same cutting-edge tools, like the CARTO™ 3D mapping system, that are standard in top-tier hospitals.

“Cardiac electrophysiology is undergoing a period of remarkable innovation, and it is important that patients treated in ambulatory surgery centers have access to the same advanced technologies available in traditional hospital settings,” said Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital. The deal ensures physicians are not forced to compromise on technology when they move to the more efficient ASC model. This is critical for maintaining quality and continuing to push the field forward.

A Structural Reset for Costs and Access

Perhaps the most significant catalyst for this revolution is economic. A landmark decision by the Centers for Medicare & Medicaid Services (CMS) to approve reimbursement for cardiac ablation procedures in ASCs, effective January 1, 2026, has opened the floodgates. This policy change represents what one industry analyst calls a “structural cost reset” for the healthcare system. For identical procedures, ASC facility fees are often 30-50% lower than those charged by hospital outpatient departments. For Medicare, this translates into projected savings of hundreds of millions of dollars annually. For patients, it means lower out-of-pocket costs and greater convenience.

The impact on patient access is equally profound. In many markets, wait times for EP procedures in crowded hospital labs can stretch for months. By expanding procedural capacity into the more nimble ASC environment, this shift can dramatically shorten those waits, allowing patients to receive treatment sooner. “By creating greater access to these technologies within physician-led ambulatory surgery centers, we can help expand treatment options for patients,” commented Dr. Arash Aryana, Medical Director of Cardiovascular Services at Mercy Medical Group. This isn't just about convenience; it's about reducing the symptom burden and improving long-term outcomes for millions of Americans suffering from arrhythmias.

Of course, this model depends on rigorous patient selection. ASCs are designed for procedures with predictable courses and low complication risks. Patients with significant comorbidities or higher-risk profiles will continue to be treated in the hospital setting. However, for a large and growing cohort of patients, the ASC model offers a safe, high-quality, and far more efficient alternative.

Physician Empowerment in a New Competitive Arena

At the center of this transition are physician-led organizations like ACCESS. Group Purchasing Organizations (GPOs) traditionally leverage collective buying power to negotiate discounts on supplies. But specialized, physician-led GPOs are evolving into strategic enablers. They provide the infrastructure that allows independent ASCs to evaluate, acquire, and implement the capital-intensive technology required to build sustainable, high-quality programs.

This agreement gives ACCESS-affiliated centers a “more efficient pathway to evaluate, acquire and implement advanced technologies,” according to Dr. Swarup. It empowers physicians to maintain clinical leadership and control over the tools they use, ensuring that the focus remains on patient-centered care even as the business model of healthcare delivery evolves.

This maneuver also illuminates the intensifying competition among MedTech giants. The ASC setting is the new battleground for market share in the multi-billion-dollar electrophysiology market. Johnson & Johnson is not alone in recognizing this. In a savvy move to ensure physician choice, ACCESS GPO also recently signed a similar agreement with Medtronic, one of J&J's primary competitors. This positions ACCESS as a key gatekeeper, offering its members access to premier technologies from multiple vendors.

Johnson & Johnson's strategy is clearly focused on dominating this emerging space. Its recent agreement to acquire Atraverse Medical, a company specializing in tools to improve access to the left atrium during ablation procedures, is another piece of the puzzle. By investing in technologies that enhance procedural efficiency and safety, Johnson & Johnson is betting that it can become the indispensable partner for the thousands of EP labs migrating to the outpatient world. This deal with ACCESS is a critical step in embedding its ecosystem deep within the next generation of cardiac care.